Reports: Odds of Getting Drugs to Market Range from 6% to 40%

A recent report written by SVB Leerink analysts that looked at eight companies and their research-and-development portfolios found that in the past five years, they progressed only 24% of their new molecular entities (NMEs) to approval. For each NME, they spent about $1 billion on average on R&D and about $5.3 billion for each approval.